You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

Image of a fictitious patient and healthcare professional

Educational Videos/Journal Articles

We have created a range of expert lead video content/journal articles and downloadable resources to support you and your advanced ovarian cancer patients who have been prescribed ZEJULA.

Videos Content

Meet the Expert Patient Case studies video

This video will breakdown and discuss the clinical considerations for selection of PARPi therapy for women with advanced ovarian cancer, the importance of an integrated patient care approach and patient considerations for dosing, administration and optimising adherence to therap

Speaker: Professor Jonathan A. Ledermann, MD, FMedSCI Consultant Medical Oncologist, Clinical Director UCL Cancer Institute, UCL Hospital London, United Kingdom

GyncancerXchange

Ovarian Cancer Experts explore the implications of the latest data supporting first-line maintenance treatment with PARPi in patients with advanced ovarian cancer.

ZEJULA Summary of Product Characteristics.

Speaker: Dr Antonio González-Martín, MD, PhD ; Prof lain McNeish,MD, PhD, FRCP ; Prof Michael Friedlander, AM, FRACP, PhD

While treatment outcomes for patients with gynaecological cancers have improved, clinical challenges and unmet needs remain. This video from global experts in the field of gynaecological cancers is a patient-centric event which aims to address key topics in first-line maintenance therapy for advanced ovarian cancer. This programme will feature discussions and insights to support treatment decision making centering on efficacy and quality of life in advanced ovarian cancer

Agenda & Objectives

Chapter 1 of 4

PARPi Monotherapy

Chapter 2 of 4

Understanding Key Drivers

Chapter 3 of 4

Patient Case

Chapter 4 of 4

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

PM-IE-NRP-WCNT-240002 | Date of Preparation: July 2024

Journal Articles

Journal Article Resources

EJC 2023: Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer2 Click Here

Authors: Gonzalez-Martin et al

Request A Contact From Our Key Account Manager

ZEJULA is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinumsensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

HCP, healthcare professional; MoA, mechanism of action; QoL, quality of life.

References

  1. ZEJULA Summary of Product Characteristics.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Zejula is a registered trademark of the GlaxoSmithKline group of companies.

June 2024 PM-IE-NRP-WCNT-240001